Details of the Drug Reposition

General Information of This Drug (ID: DMK0UOY)

Drug Name
ME-401   DMK0UOY
Synonyms
Zandelisib; UNII-8Z28M5SX0X; 8Z28M5SX0X; 4-yl)-1,3,5-triazin-2-amine; 1401436-95-0; [2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl}-6-(morpholin-; 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-N-{2-methyl-1-; Zandelisib [INN]; Zandelisib [USAN]; SCHEMBL12936730; GTPL10627; ACC-524; PWT-143; ME401; PW-143; WHO 11202; ZINC148868634; Example 51 [WO2012135160A1]; HY-109198; CS-0119144; A35 [WO2012135160A1]; 1,3,5-Triazin-2-amine, 4-(2-(difluoromethyl)-1H-benzimidazol-1-yl)-N-(1,1-dimethyl-2-(2-(1-methyl-4-piperidinyl)phenyl)ethyl)-6-(4-morpholinyl)-; 4-(2-(Difluoromethyl)benzimidazol-1-yl)-N-(1,1-dimethyl-2-(2-(1-methyl-4-piperidyl)phenyl)ethyl)-6-morpholino-1,3,5-triazin-2-amine; 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Follicular lymphoma DISVEUR6 2A80 Phase 1 [1]
Lymphoma DISN6V4S 2A80-2A86 Phase 1 [1]
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 1 [1]
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)